Entera Bio (NASDAQ:ENTX) Shares Up 5.2% – Should You Buy?

Entera Bio Ltd. (NASDAQ:ENTX)’s stock price traded up 5.2% during trading on Wednesday . The company traded as high as $3.05 and last traded at $3.01. 434,847 shares were traded during mid-day trading, a decline of 59% from the average session volume of 1,054,112 shares. The stock had previously closed at $2.86.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Wall Street Zen upgraded Entera Bio to a “sell” rating in a report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Entera Bio in a report on Friday, July 17th. Finally, HC Wainwright reiterated a “buy” rating on shares of Entera Bio in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Entera Bio presently has an average rating of “Hold” and a consensus price target of $9.00.

Entera Bio Trading Up 2.4%

The business’s 50 day simple moving average is $2.77 and its 200 day simple moving average is $1.81. The firm has a market capitalization of $526.70 million, a PE ratio of -8.66 and a beta of 1.38.

Entera Bio (NASDAQ:ENTX) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06).

Hedge Funds Weigh In On Entera Bio

A hedge fund recently raised its stake in Entera Bio stock. Seven Fleet Capital Management LP increased its stake in shares of Entera Bio Ltd. (NASDAQ:ENTX) by 51.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 205,542 shares of the company’s stock after purchasing an additional 70,224 shares during the quarter. Seven Fleet Capital Management LP owned 0.42% of Entera Bio worth $228,000 at the end of the most recent quarter. 14.11% of the stock is currently owned by institutional investors and hedge funds.

Entera Bio Company Profile

Entera Bio Ltd. is a biotechnology company developing orally administered therapies based on large-molecule drugs, including proteins and peptides that are traditionally delivered by injection. The company’s proprietary delivery technology is designed to help these molecules pass through the gastrointestinal tract and reach the bloodstream, with the goal of improving convenience and patient adherence.

Entera Bio’s lead programs have focused on bone and mineral disorders. Its pipeline has included EB613, an oral formulation of parathyroid hormone (PTH 1-34, or teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral PTH product candidate intended for hypoparathyroidism.